cgp - a close above 3.5cents would trigger a , page-36

I aint no downramper or have intentions to buy this stock until this company has some credability. Management doesnt appear to have put much of their own money into buying shares either. This company has stated in the past it will do further clinical tests to validate that the increase in airflow means an improvement in exercise performance. This hasnt been done yet , other than a whole bunch of athletes mentioning their opinions. Measured clinical tests proving improved exercise performance is whats needed to get me interested in this stock.

"The company said Breatheassist was “a miniature, virtually invisible nasal cannula worn within the nostrils” with applications in sports performance enhancement; drug delivery;reducing snoring; and filtration of pollen or airborne contaminants to reduce the risk associated with allergic rhinitis or other respiratory or influenza infections.

Helicon said a clinical trial at Melbourne’s Royal Victorian Eye and Ear Hospital of 20 healthy subjects showed that Breathassist resulted in a statistically significant 37.6
percent increase in nasal airflow over baseline, as measured objectively by rhinomanometry.

The company said further clinical tests would be conducted to further validate the improvement in airflow and to correlate this data with an increase in exercise
performance."

http://www.biotechdaily.com.au/media/backissues/2011/08%20Aug/BD%20Biotech%20Daily%20Aug%2023.pdf